Indo US Bio-Tech (NSE:INDOUS) Piotroski F-Score: 2 (As of Jun. 29, 2026) — 60% Below Median


NSE:INDOUS Indo US Bio-Tech Ltd NSE:INDOUS
63 GF Score
Price ₹88.75
GF Value ₹197.21
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Indo US Bio-Tech Piotroski F-Score?

Indo US Bio-Tech NSE:INDOUS -0.27% 63 Piotroski F-Score is 2 as of Jun. 29, 2026, which is 60% below its 10-year median of 5.00. GuruFocus rates NSE:INDOUS with a GF Score™ of 63/100 and a GF Value™ of ₹197.21 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 251 Agriculture companies, Indo US Bio-Tech ranks worse than 89.24% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Indo US Bio-Tech has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Indo US Bio-Tech's Piotroski F-Score or its related term are showing as below:

NSE:INDOUS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 2

During the past 13 years, the highest Piotroski F-Score of Indo US Bio-Tech was 7. The lowest was 2. And the median was 5.

Indo US Bio-Tech  (NSE:INDOUS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Indo US Bio-Tech Piotroski F-Score Related Terms


Indo US Bio-Tech Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Indo US Bio-Tech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo US Bio-Tech Piotroski F-Score Chart

Indo US Bio-Tech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 3.00 7.00 2.00

Indo US Bio-Tech Quarterly Data
Mar20 Sep20 Mar21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 0.00 0.00 0.00 2.00

NSE:INDOUS vs CTVA, CF, MOS: Piotroski F-Score Comparison

For the Agricultural Inputs subindustry, Indo US Bio-Tech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indo US Bio-Tech Piotroski F-Score vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Indo US Bio-Tech's Piotroski F-Score falls into.


NSE:INDOUS
63GF Score
Indo US Bio-Tech Ltd NSE:INDOUS
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹131 Mil.
Cash Flow from Operations was ₹-126 Mil.
Revenue was ₹1,104 Mil.
Gross Profit was ₹302 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (978.427 + 1330.967) / 2 = ₹1154.697 Mil.
Total Assets at the begining of this year (Mar25) was ₹978 Mil.
Long-Term Debt & Capital Lease Obligation was ₹10 Mil.
Total Current Assets was ₹1,207 Mil.
Total Current Liabilities was ₹395 Mil.
Net Income was ₹163 Mil.

Revenue was ₹1,038 Mil.
Gross Profit was ₹312 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (844.563 + 978.427) / 2 = ₹911.495 Mil.
Total Assets at the begining of last year (Mar24) was ₹845 Mil.
Long-Term Debt & Capital Lease Obligation was ₹29 Mil.
Total Current Assets was ₹867 Mil.
Total Current Liabilities was ₹163 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Indo US Bio-Tech's current Net Income (TTM) was 131. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Indo US Bio-Tech's current Cash Flow from Operations (TTM) was -126. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=131.229/978.427
=0.13412242

ROA (Last Year)=Net Income/Total Assets (Mar24)
=162.674/844.563
=0.19261322

Indo US Bio-Tech's return on assets of this year was 0.13412242. Indo US Bio-Tech's return on assets of last year was 0.19261322. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Indo US Bio-Tech's current Net Income (TTM) was 131. Indo US Bio-Tech's current Cash Flow from Operations (TTM) was -126. ==> -126 <= 131 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=9.519/1154.697
=0.00824372

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=29.344/911.495
=0.03219326

Indo US Bio-Tech's gearing of this year was 0.00824372. Indo US Bio-Tech's gearing of last year was 0.03219326. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1206.918/395.225
=3.05374913

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=867.266/163.39
=5.3079503

Indo US Bio-Tech's current ratio of this year was 3.05374913. Indo US Bio-Tech's current ratio of last year was 5.3079503. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Indo US Bio-Tech's number of shares in issue this year was 20.066. Indo US Bio-Tech's number of shares in issue last year was 20.058. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=301.688/1104.391
=0.27317137

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=311.809/1038.384
=0.30028294

Indo US Bio-Tech's gross margin of this year was 0.27317137. Indo US Bio-Tech's gross margin of last year was 0.30028294. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1104.391/978.427
=1.12874134

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1038.384/844.563
=1.22949265

Indo US Bio-Tech's asset turnover of this year was 1.12874134. Indo US Bio-Tech's asset turnover of last year was 1.22949265. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Indo US Bio-Tech has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
Indo US Bio-Tech (NSE:INDOUS) has a Piotroski F-Score of 2 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Indo US Bio-Tech and its competitors. This is 60% below median its historical median of 5.00. Over the past decade, Indo US Bio-Tech's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Indo US Bio-Tech ranks #224 out of 251 companies in the Agriculture industry, placing it in the top 89.2%.
Is Indo US Bio-Tech's Piotroski F-Score too high?
Indo US Bio-Tech's current Piotroski F-Score of 2 is 60% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Agriculture industry median Piotroski F-Score is 5.00. Indo US Bio-Tech's value of 2 is 60% below this industry median. Based on the distribution chart, Indo US Bio-Tech ranks #224 out of 251 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Indo US Bio-Tech has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Piotroski F-Score compare to CTVA and CF?
According to the Agriculture industry distribution chart, Indo US Bio-Tech ranks #224 out of 251 companies for Piotroski F-Score. This places Indo US Bio-Tech in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Indo US Bio-Tech's value of 2 is 60% below this benchmark. Historically, Indo US Bio-Tech's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Indo US Bio-Tech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for an Agriculture company?
The median Piotroski F-Score among Agriculture companies is 5.00, based on 251 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Indo US Bio-Tech and its competitors. For the Agriculture industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current Piotroski F-Score is 2, which is 60% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹197.21, compared to a current price of ₹88.75 — trading 55% below its estimated fair value. The current Piotroski F-Score is 2, which is 60% below median its 10-year median of 5.00 and 60% below the Agriculture industry median of 5.00. Indo US Bio-Tech's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current Piotroski F-Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?

Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued. The current stock price of ₹88.75 is trading 55% below its estimated GF Value™ of ₹197.21. GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.

Key valuation signals for NSE:INDOUS:

  • Piotroski F-Score: 2 (60% below median its 10-year median of 5.00)
  • GF Value™: ₹197.21 vs. price of ₹88.75 (55% below fair value)
  • GF Score™: 63/100 with 5 warning signs
  • Industry Position: 60% below the Agriculture median (#224 of 251)

No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indo US Bio-Tech Business Description

Other Exchanges 541304:India
Address Satadhar Char Rasta, Sola Road, 309, Shanti Mall, Opposite Navrang Tower, Ahmedabad, GJ, IND, 380061
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
63GF Score

Get the complete analysis for NSE:INDOUS

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹88.75
Price
₹197.21
GF Value